02:43 , Jun 1, 2019 |  BioCentury  |  Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
23:23 , Feb 20, 2019 |  BC Innovations  |  Distillery Therapeutics

Endocrine/metabolic

INDICATION: Diabetes Mouse studies suggest agonizing GITR could help treat insulin resistance. In genetic and high-fat diet-induced mouse models of insulin resistance, a GITR agonist mAb increased glucose tolerance and insulin sensitivity and decreased fasting...
19:30 , Dec 21, 2018 |  BC Week In Review  |  Company News

Astellas exercises option to acquire Potenza

Astellas Pharma Inc. (Tokyo:4503) exercised an exclusive option under an April 2015 deal and acquired Potenza Therapeutics Inc. (Cambridge, Mass.) (see "Potenza Therapeutics, Astellas Deal" ). Potenza received $164.6 million up front and is eligible...
20:15 , Mar 23, 2018 |  BioCentury  |  Emerging Company Profile

Double threat

Boston Immune Technologies & Therapeutics Inc. is developing potentially first-in-class TNFR2 inhibitors that have the dual effect of killing both tumor cells and immunosuppressive Tregs. President and CEO Russell LaMontagne said tumor necrosis factor receptor...
21:42 , Oct 27, 2017 |  BC Week In Review  |  Company News

Incyte gains rights to Macrogenics' PD-1 inhibitor

MacroGenics Inc. (NASDAQ:MGNX) granted Incyte Corp. (NASDAQ:INCY) an exclusive, worldwide license to develop and commercialize PD-1 inhibitor MGA012 . MacroGenics retains rights to develop combinations that include the mAb and its pipeline assets. MacroGenics is...
21:31 , Oct 25, 2017 |  BC Extra  |  Company News

Incyte gains rights to MacroGenics' PD-1 inhibitor

MacroGenics Inc. (NASDAQ:MGNX) granted Incyte Corp. (NASDAQ:INCY) an exclusive, worldwide license to develop and commercialize PD-1 inhibitor MGA012 . MacroGenics, which retains rights to develop combinations that include the mAb and its pipeline assets, climbed...
18:10 , Sep 15, 2017 |  BC Week In Review  |  Company News

Five Prime ends antibody deal with Inhibrx

Five Prime Therapeutics Inc. (NASDAQ:FPRX) said it will terminate a 2015 deal with Inhibrx LLC (La Jolla, Calif.) to develop and commercialize Inhibrx’s preclinical glucocorticoid-induced tumor necrosis factor receptor (TNFR)-related protein (GITR; TNFRSF18) antibody program....
10:21 , Aug 24, 2017 |  BC Innovations  |  Product R&D

MedImmune's neo stimulus package

The MedImmune LLC unit of AstraZeneca plc thinks its pipeline of immune stimulators will give it an edge in the crowded field of neoantigen cancer vaccines. The company's strategy raises the question of whether the...
18:11 , Jun 16, 2017 |  BioCentury  |  Product Development

Everywhere IDO

Incyte Corp. and partner Merck & Co. Inc. now have reported the data that led them to plan Phase III trials that combine their molecules in five cancer indications. For Incyte, the next step is...
01:05 , Apr 21, 2017 |  BC Innovations  |  Product R&D

Making marks at AACR

Biomarkers that could stratify patients, point to treatment combinations or predict toxicity were a major part of the conversation at this year’s AACR conference, where they emerged as potential difference makers for a range of...